The Role of the L-Arginine–Nitric Oxide Molecular Pathway in Autosomal Dominant Polycystic Kidney Disease

Corina Daniela Ene,Mircea Penescu,Ilinca Nicolae,Cristina Capusa

DOI: https://doi.org/10.3390/jpm14030299

IF: 3.5083

2024-03-12

Journal of Personalized Medicine

Abstract:Recently, arginine has been proven to play an important role in ADPKD physiopathology. Arginine auxotrophy in ADPKD induces cell hyperproliferation, blocking the normal differentiation of renal tube cells and causing cyst formation. We explored the L-arginine (Arg)–nitric oxide (NO) molecular pathway in ADPKD, a multisystemic arginine auxotrophe disease. We developed a prospective case–control study that included a group of 62 ADPKD subjects with an estimated filtration rate over 60 mL/min/1.73 mp, 26 subjects with chronic kidney disease with an eGFR > 60 mL/min/1.73 mp, and a group of 37 healthy subjects. The laboratory determinations were the serum level of arginine, the enzymatic activity of arginase 2 and inducible nitric oxide synthase, the serum levels of the stable metabolites of nitric oxide (nitrate, direct nitrite, and total nitrite), and the endogenous inhibitors of nitric oxide synthesis (asymmetric dimethylarginine and symmetric dimethylarginine). In the ADPKD group, the levels of the arginine and nitric oxide metabolites were low, while the levels of the metabolization enzymes were higher compared to the control group. Statistical analysis of the correlations showed a positive association between the serum levels of Arg and the eGFR and a negative association between Arg and albuminuria. ADPKD is a metabolic kidney disease that is auxotrophic for arginine. Exploring arginine reprogramming and L-Arg–NO pathways could be an important element in the understanding of the pathogenesis and progression of ADPKD.

medicine, general & internal,health care sciences & services

What problem does this paper attempt to address?

This paper attempts to explore the role of the L - arginine (L - Arginine, L - Arg) - nitric oxide (Nitric Oxide, NO) molecular pathway in autosomal dominant polycystic kidney disease (Autosomal Dominant Polycystic Kidney Disease, ADPKD). ADPKD is a metabolic disease characterized by an increased demand for arginine, leading to abnormal cell proliferation and cyst formation. By analyzing the levels of L - Arg and NO and their metabolites, the study aims to reveal the potential roles of these molecules in the pathogenesis and progression of ADPKD, providing a new perspective for understanding the pathophysiological process of the disease. Specifically, the paper focuses on the following aspects: 1. **Metabolism of L - arginine and nitric oxide**: The levels of L - Arg, NO and their metabolites (such as nitrate, direct nitrite, total nitrite, asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA)) in the serum of ADPKD patients were studied and compared with those of chronic kidney disease (Chronic Kidney Disease, CKD) patients and healthy control groups. 2. **Changes in enzyme activity**: The activity changes of arginase 2 (Arginase 2, ARG2) and inducible nitric oxide synthase (Inducible Nitric Oxide Synthase, iNOS) in the serum of ADPKD patients were evaluated. These enzymes play key roles in the metabolic process of L - Arg. 3. **Correlation analysis**: Through statistical analysis, the relationships between L - Arg and NO metabolites and renal function indicators (such as estimated glomerular filtration rate (Estimated Glomerular Filtration Rate, eGFR)) and urinary proteins (such as albuminuria) were explored. The research results show that the serum L - Arg level in ADPKD patients is significantly lower than that in the healthy control group, while the activities of ARG2 and iNOS are relatively high. In addition, the L - Arg level is positively correlated with eGFR and negatively correlated with albuminuria. These findings suggest that the L - Arg - NO molecular pathway may play an important role in the pathogenesis of ADPKD. Further research on this pathway is helpful for better understanding the development of the disease and finding potential treatment targets.

The Role of the L-Arginine–Nitric Oxide Molecular Pathway in Autosomal Dominant Polycystic Kidney Disease

Long-term dietary nitrate supplementation does not reduce renal cyst growth in experimental autosomal dominant polycystic kidney disease

Asymmetric Dimethylarginine and Lipid Peroxidation Products in Early Autosomal Dominant Polycystic Kidney Disease

Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function

Exploring Adiponectin in Autosomal Dominant Kidney Disease: Insight and Implications

Endothelium-dependent Relaxation of Small Resistance Vessels is Impaired in Patients with Autosomal Dominant Polycystic Kidney Disease.

The Influence of Non-Pharmacological and Pharmacological Interventions on the Course of Autosomal Dominant Polycystic Kidney Disease

The Expression and Activity of Renal Nitric Oxide Synthase and Circulating Nitric Oxide in Polycystic Kidney Disease Rats.

Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism

A Link between the Intrarenal Renin Angiotensin System and Hypertension in Autosomal Dominant Polycystic Kidney Disease

Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling

The Genetic and Cellular Basis of Autosomal Dominant Polycystic Kidney Disease-A Primer for Clinicians

Early Markers of Cardiovascular Risk in Autosomal Dominant Polycystic Kidney Disease

The Effect of Sodium and Angiotensin-Converting Enzyme Inhibition on the Classic Circulating Renin–angiotensin System in Autosomal-Dominant Polycystic Kidney Disease Patients

Potential Add-On Benefits of Dietary Intervention in the Treatment of Autosomal Dominant Polycystic Kidney Disease

Therapeutic advances in ADPKD: the future awaits

Role of MicroRNAs in Autosomal Dominant Polycystic Kidney Disease: Expression Profiles and Pathway Analysis

Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open?

Biomarkers of Kidney Disease Progression in ADPKD

[Current opinions on the etiology and pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). II. Factors other than genetic factors which have an influence on disease course and selected clinical problems]

Inhibition of asparagine synthetase effectively retards polycystic kidney disease progression